Other combination strategies include MEK inhibitors in melanoma and pancreatic cancer [28], general control nonderepressible 2 (GCN2) inhibitors in pancreatic cancer [29], and the glutamine antagonist DON in pancreatic cancer [18]. This evidence concerns the gene MAP2K7 and familial pancreatic carcinoma.